A 3-year follow-up of patients with refractory/relapsed indolent non-Hodgkin (NHL) treated with a combination of magrolimab ...
Patients are preselected for CDKN2A and/or CDKN2B abnormalities - - Safety and efficacy data to be reported at an upcoming oncology medical conference - BERKELEY HEIGHTS, N.J., Sept. 25, 2024 (GLOBE ...
The Securities and Exchange Board of India (SEBI) on Wednesday launched a dedicated Foreign Portfolio Investor (FPI) outreach ...
During a Case-Based Roundtable® event, Matthew A. Lunning, DO, discussed the updated trial data for 2 chimeric antigen ...
In an interview with Targeted Oncology, Mark R. Litzow, MD, discussed the incorporation of Immunotherapy into upfront acute ...
The two companies will jointly conduct a registrational Phase III study of the Bcl-2 inhibitor ... This overexpression contributes to tumor cell proliferation through cell cycle dysregulation, ...
Japan’s MHLF approves Padcev with Keytruda for first-line treatment of radically unresectable urothelial carcinoma: Tokyo Wednesday, September 25, 2024, 11:00 Hrs [IST] Astellas ...
Rather than a ground-up redesign, the 2026 Hyundai Nexo fuel-cell SUV is believed to build on the outgoing model in every respect ...
HANSIZHUANG (serplulimab) is the world's first anti-PD-1 mAb for first-line treatment of ES- SCLC - HANSIZHUANG (serplulimab) is expected to become the first and only anti-PD-1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback